Background {#Sec1}
==========

Mammographic density (MD) is a risk factor for breast cancer \[[@CR1]--[@CR5]\] and is also known to play a role in the masking of the tumor \[[@CR1], [@CR2], [@CR5]\]. What is unclear is whether the influences of MD on inherent risk and masking vary by tumor characteristics. Knowledge on this might aid to understand the aetiology of breast cancer. Specifically, understanding if the dense tissues of the breast give rise to breast tumors of a specific kind might aid in understanding the biological mechanisms involved in the development of breast tumors. Understanding if masking varies by tumor characteristics might highlight the difference in the biology of the various tumors.

In a previous paper \[[@CR6]\], we postulated that the risk of screen-detected breast cancer is mostly influenced by inherent risk, while risk of interval breast cancer is due to a combination of inherent risk and risk of masking. Therefore, given a woman participating in a screening program is diagnosed with breast cancer, the factors associated to the likelihood of having a screen-detected versus an interval cancer will mostly be those that influence risk of masking. We reported in the paper that inherent risk was predicted by body mass index (BMI) and dense area (DA) or percent dense area (PDA), but not by non-dense area (NDA), whereas masking was best predicted by PDA but not BMI \[[@CR6]\].

Very few studies have analysed the association between MD and risk of breast cancer by tumor characteristics, separately for each detection mode \[[@CR7]--[@CR10]\]. Of these one study did not adjust for BMI \[[@CR9]\], the rest did not allow for the association between BMI and risk to vary by age \[[@CR7], [@CR8], [@CR10]\] and none of them had investigated the concurrent associations of dense area (DA), percent dense area (PDA) and non-dense area (NDA).

For screen-detected cancer, studies have observed that higher density was associated with increased risk of larger tumors \[[@CR7], [@CR10]\] and nodal involvement \[[@CR7]\] after adjusting for BMI. Results for interval cancer are more varied. One study observed a negative association between density and histologic grade, differentiation and mitotic index after adjusting for BMI but there was no statistically significant difference in the risk estimates between screen-detected and interval cases \[[@CR10]\]. This might not be surprising as 66% of the interval cases were true interval cases thus, the risk of interval cancer would most likely reflect inherent risk similar to risk of screen-detected cancer as postulated in our paper. Another study had combined interval cases with clinically detected cases (i.e. women with breast symptoms referred to for mammography) and reported density to be positively associated for oestrogen (ER)- and triple-negative tumors \[[@CR8]\] and larger tumors \[[@CR7]\] after adjusting for BMI.

Here we have used the same case-control study nested within the Melbourne Collaborative Cohort Study (MCCS) analysed before \[[@CR6]\], to investigate if the association between DA, PDA and NDA and inherent risk of breast cancer, and the risk of masking vary by tumor characteristics, specifically size, grade, lymph node involvement, and ER, progesterone (PR), and human epidermal growth factor receptor 2 (HER2) status.

Methods {#Sec2}
=======

The MCCS is a prospective cohort study, which started recruiting participants from the Melbourne metropolitan area between 1990 and 1994. At study entry there were 41,514 participants (including 24,469 women) aged between 27 and 76 years. A nested case-control study was designed based on the subset of MCCS women who had been identified to have attended BreastScreen Victoria, a population-based screening program, through a record linkage conducted in 2009 (20,444 women). Cases were women who subsequently had a first diagnosis of invasive adenocarcinoma of the breast (International Classification of Diseases for Oncology codes C50.0--C50.9). Four controls were matched to each case by year of birth, year of entry into the MCCS and country of origin. The mammogram with craniocaudal view and closest to study entry was chosen for measurement. Screen-detected cases were identified at BreastScreen Victoria. Cases diagnosed within 2 years of a negative screen at BreastScreen Victoria were defined as interval cases. There were 244 screen-detected cases matched to 700 controls and 148 interval cases matched to 446 controls. Further details about the nested case-control study have been published elsewhere \[[@CR6], [@CR11], [@CR12]\].

Tumor characteristics {#Sec3}
---------------------

The Victorian Cancer Registry (VCR) reviewed the pathology reports and classified the cancers according to tumor size, tumor grade, lymph node involvement, and ER, PR, and HER2 status. The original diagnostic tumor slides were retrieved for 85% of the cases from pathology laboratories and reviewed by a single pathologist (C. McLean) who assessed ER, PR, and HER2 status using immunohistochemistry techniques \[[@CR13]\]. ER and PR tumors were categorized as positive if ≥ 1% of the nuclei were stained and/or the intensity of staining was weak, moderate, or strong and negative otherwise; HER2 tumors were categorized as positive if \> 10% of the nuclei were stained and the intensity of staining was weak, moderate, or strong and negative otherwise. The agreements between the ER, PR, and HER2 status assessed by immunohistochemistry and the records held by the VCR were 91%, 70%, and 72%, respectively (for ER, κ = 0.56, *P* \< 0.0001; for PR, κ = 0.30, *P* \< 0.0001; for HER2, κ = 0.32, *P* \< 0.0001). Given the good agreement between the ER, PR, and HER2 data, when archival tumor tissue was not available, ER, PR, and HER2 status was assigned according to the histopathology reports held at the VCR.

Statistical analyses {#Sec4}
--------------------

Associations between the mammographic measures and risk were estimated in terms of odds per adjusted standard deviation (OPERA) according to models with different combinations of the variables, DA, PDA, NDA and BMI, as mentioned in our previous publication \[[@CR6]\]. Further details about OPERA have been published elsewhere \[[@CR14]--[@CR16]\].

Firstly, by applying the Box-Cox method for transforming variables to the mammographic measures of the control group, DA, PDA and NDA were transformed to (DA^0.2^--1)/0.2, (PDA^0.2^--1)/0.2 and (NDA^0.5^--1)/0.5, respectively. Linear regression was applied on each transformed mammographic measure, adjusting for age at mammogram, BMI (standardized according to the controls) and all the matching variables, and the residuals were standardized to have zero mean and unit variance. Conditional logistic regression of case-control status was then applied separately for screen-detected and interval cancers and for each tumour characteristic. The type-specific OPERA estimates were obtained by fitting an interaction term between the standardised residuals and a set-specific variable equal to the tumour type of the matching case. Heterogeneity by tumor characteristics was assessed using likelihood ratio test. Age at mammogram was fitted as a potential confounder.

For the models that included BMI measured at the MCCS study entry, we fitted an interaction between BMI (standardized based on the controls) and reference age (age at diagnosis for the case and for her matched controls) and its significance was assessed using the likelihood ratio test. We have reported the risk estimates for BMI at ages 50 and 70 to show the predicted risks corresponding to the pre- and postmenopausal age groups.

For the analyses of interval versus a screen-detected breast cancers, unconditional logistic regression was applied only to cases adjusted for age at mammogram. Association between BMI and risk of interval versus a screen-detected breast cancer did not depended on age at diagnosis.

The Bayesian information criterion (BIC) and the area under the receiver operating characteristic curve (AUC) were used to test for relative goodness of fit. Differences between AUCs were tested using the De Long's tests \[[@CR17]\].

Sensitivity analyses were conducted in which we further adjusted for potential confounders: BMI at age 18--21 years; age at menarche; parity and lactation; menopausal status; HRT use; OC use; alcohol consumption and energy intake; and the matching variables (country of birth, year of birth, year of cohort entry and reference age) using unconditional logistic regression. We further adjusted for family history of breast cancer. A sensitivity analysis was also conducted by excluding cases diagnosed within 2 years from the mammogram, and their matching controls.

A more detailed explanation of the method used to derive OPERA has been given in our previous publication \[[@CR6]\].

Statistical analyses were performed using Stata 12.1 (Stata Corporation, College Station, TX). Two-sided *P* \< 0.05 was considered to be nominally statistically significant.

Results {#Sec5}
=======

As shown in Table [1](#Tab1){ref-type="table"}, screen-detected cases were on average about 2 to 3 years older than interval cases at diagnosis (65 years vs 62 years, *P* \< 0.001), at study entry when covariates were measured (56 years vs 54 years, *P* = 0.01), and at the mammogram closest to study entry (59 years vs 57 years, *P* \< 0.01). Interval cases had on average greater DA and PDA and lesser total breast area and NDA than screen-detected cases (*P* \< 0.01). There was no significant difference in BMI and all the other confounders except for menopausal status and alcohol consumption between the two types of cases. Within the screen-detected cases there were a higher percentage of menopausal women (*P* = 0.02) and lower percentage of alcohol consumers (*P* \< 0.01) at cohort entry than the interval cases.Table 1Characteristics of study participantsScreen-detected casesControlsInterval casesControls(*N* = 244)(*N* = 700)(*N* = 148)(*N* = 446)Mean (SD)Mean (SD)Mean (SD)Mean (SD)Age at baseline, years56 (8)56 (8)54 (8)54 (8)Age at mammogram, years59 (7)59 (7)57 (7)57 (7)Age at diagnosis, years65 (7)62 (7)Time between age at mammogram and reference age, years6 (3)6 (3)5 (3)5 (4)Total energy intake, MJ/day8.4 (2.9)8.6 (3.5)8.7 (3.2)8.7 (3.1)BMI, kg/m2 All women27.5 (4.9)26.7 (4.9)26.7 (5.3)26.5 (4.8) Premenopausal27.2 (5.7)26.2 (5.0)25.9 (4.9)26.1 (4.6) Postmenopausal27.6 (4.6)27.0 (4.9)27.2 (5.5)26.7 (5.0)BMI at age 18--21 years, kg/m221.5 (2.9)21.5 (2.9)21.4 (2.5)21.5 (2.8)Breast Total area, cm2143.7 (60.9)137.8 (57.6)125.0 (56.9)133.4 (60.3) Non-dense area, cm2124.2 (62.1)120.9 (58.8)96.5 (55.6)115.3 (60.6) Dense area, cm219.6 (21.7)16.8 (20.6)28.5 (24.5)18.1 (19.4) Percent mammographic density, %15.5 (15.7)14.0 (15.3)25.2 (17.9)15.4 (14.7)Country of birthN (%)N (%)N (%)N (%) Anglo Saxon/ Other204 (84)583 (83)123 (83)371 (83) Italy25 (10)74 (11)13 (9)40 (9) Greece15 (6)43 (6)12 (8)35 (8)Age at menarche, years \< 1247 (19)125 (18)31 (21)75 (17) 1252 (21)145 (21)25 (17)86 (19) 1355 (23)169 (24)36 (24)111 (25) 14+88 (36)261 (37)56 (38)174 (39)Parity and lactation Nulliparous38 (16)84 (12)25 (17)62 (14) Parous, never lactated10 (4)61 (9)12 (8)34 (8) Parous, lactated190 (78)542 (77)108 (73)343 (77)Menopausal status Premenopausal69 (28)195 (28)59 (40)170 (38) Postmenopausal174 (71)504 (72)89 (60)275 (62)Hormone replacement therapy use Never169 (69)493 (70)98 (66)323 (72) Ever74 (30)205 (29)49 (33)122 (27)Oral contraceptive use Never93 (38)283 (40)58 (39)157 (35) Ever150 (61)415 (59)90 (61)287 (64)Alcohol consumption Lifetime abstainers109 (45)257 (37)43 (29)160 (36) Ex-drinkers13 (5)24 (3)3 (2)13 (3) Low intake, 1--19 g/day97 (40)337 (48)78 (53)223 (50) Medium intake, 20--39 g/day19 (8)61 (9)20 (14)38 (9) High intake, ≥ 40 g/day6 (2)21 (3)4 (3)12 (3)Family history of breast cancer^a^ No185 (76)548 (78)101 (68)341 (76) Yes38 (16)77 (11)30 (20)43 (10)ER Positive188 (77.0)94 (63.5) Negative45 (18.4)45 (30.4)PR Positive126 (51.6)57 (38.5) Negative106 (43.4)80 (54.1)HER2 Positive73 (29.9)41 (27.7) Negative153 (62.7)96 (64.9)Grade Well differentiated62 (25.4)24 (16.2) Moderately differentiated104 (42.6)52 (35.1) Poorly differentiated65 (26.6)61 (41.2)Size \< 1 cm76 (31.1)25 (16.9) 1--2 cm116 (47.5)51 (34.5) ≥ 2 cm49 (20.1)65 (43.9)Nodal Status Positive39 (16.0)65 (43.9) Negative190 (77.9)71 (48.0)*Abbreviations*: *BMI* body mass index, *SD* standard deviation^a^Family history of breast cancer is defined as having any relative with breast cancer

ER, PR and HER2 status was known for 95%, 94% and 93% of the cases, respectively. Within the cases with known ER, PR or HER2 status, 282 (76%) were ER+, 183 (50%) were PR+, and 114 (31%) were HER2+. Grade was known for 94% of the cases, which included 86 (23%) well differentiated, 156 (42%) moderately differentiated, and 126 (34%) poorly differentiated tumors. Lymph node involvement was known for 93% of the cases of whom 104 (28%) were node positive. Size of the tumor was known for 97% of the cases for which 101 (26%) were \< 1 cm, 167 (44%) were between 1 to 2 cm and 114 (30%) were ≥ 2 cm.

Interval cases had more tumors with features predictive of poorer prognosis than screen-detected cases; ER- (30% vs 18%, *P* \< 0.01), PR- (54% vs 43%, *P* = 0.02), poorly differentiated tumors (41% vs 27%, *P* \< 0.01), positive nodal status (44% vs 16%, *P* \< 0.001) and larger tumor size, ≥ 2 cm (44% vs 20%, *P* \< 0.001).

Table [2](#Tab2){ref-type="table"} shows that both DA and PDA were positively associated with risk of larger breast tumors with an increase in risk of about 80% and 110% for tumors of size 2 cm and greater, respectively, per adjusted SD under all models (all test for heterogeneity by tumour size, *p* \< 0.01); the risk was significant but lower for tumors of size 1--2 cm and not significant for smaller tumours of size lesser than 1 cm. DA and PDA also were positively associated with positive lymph nodes with risk gradients of about 90% and 110%, respectively, per adjusted SD under all models; whereas the risk associated to negative lymph nodes was lower (all test for heterogeneity by nodal status, p \< 0.01). The model including only PDA gave the best fit when analysing tumor size (BIC = 1110, AUC = 0.68) and lymph node involvement (BIC = 1041, AUC = 0.68). BMI and NDA were not associated with the size of the tumor and nodal involvement under any model. None of the three mammographic measures and BMI were associated with the other tumor characteristics.Table 2Risk of breast cancer for BMI and mammographic measures by tumor characteristicsOPERA (95% CI)Cases/ controlsBMI + DA + NDABMI + PDABMI + DADA + NDAPDADAERBIC, AUC1130, 0.671117, 0.671130, 0.661108, 0.671094, 0.661107, 0.65BMI per 1 SD at age 50 Positive314/ 9160.82 (0.61,1.11)0.83 (0.61,1.12)0.82 (0.60,1.11) Negative106/ 3160.93 (0.62,1.41)0.91 (0.60,1.36)0.89 (0.59,1.35)BMI per 1 SD at age 70 Positive1.23 (1.04,1.46)1.23 (1.04,1.45)1.23 (1.04,1.45) Negative1.12 (0.79,1.60)1.12 (0.79,1.60)1.11 (0.78,1.58)P ~for\ interaction\ with\ age~ = 0.07P ~for\ interaction\ with\ age~ = 0.08P ~for\ interaction\ with\ age~ = 0.06*P* = 0.83*P* = 0.88*P* = 0.86DA per *adjusted* 1SD Positive1.32 (1.16,1.51)1.34 (1.18,1.53)1.33 (1.17,1.52)1.35 (1.19,1.54) Negative1.50 (1.18,1.90)1.54 (1.21,1.95)1.49 (1.18,1.89)1.52 (1.21,1.92)*P* = 0.36*P* = 0.33*P* = 0.41*P* = 0.38PDA per *adjusted* 1SD Positive1.42 (1.24,1.63)1.43 (1.25,1.64) Negative1.72 (1.33,2.23)1.71 (1.32,2.20)*P* = 0.20*P* = 0.23NDA per *adjusted* 1SD Positive0.86 (0.76,0.98)0.86 (0.76,0.98) Negative0.69 (0.54,0.88)0.69 (0.54,0.88)*P* = 0.10*P* = 0.10PRBIC, AUC1115, 0.681101, 0.681113, 0.671099, 0.671085, 0.661097, 0.65BMI per 1 SD at age 50 Positive206/ 6040.77 (0.54,1.10)0.78 (0.55,1.11)0.77 (0.54,1.10) Negative210/ 6150.98 (0.70,1.36)0.96 (0.69,1.33)0.93 (0.67,1.30)BMI per 1 SD at age 70 Positive1.46 (1.18,1.81)1.46 (1.18,1.80)1.46 (1.18,1.80) Negative0.95 (0.76,1.19)0.94 (0.75,1.18)0.95 (0.75,1.18)P ~for\ interaction\ with\ age~ = 0.01P ~for\ interaction\ with\ age~ = 0.02P ~for\ interaction\ with\ age~ = 0.02P = 0.02*P* = 0.02*P* = 0.02DA per *adjusted* 1SD Positive1.35 (1.15,1.59)1.36 (1.16,1.60)1.35 (1.15,1.59)1.36 (1.16,1.60) Negative1.36 (1.16,1.60)1.43 (1.21,1.68)1.36 (1.16,1.60)1.42 (1.21,1.67)*P* = 0.96*P* = 0.69*P* = 0.97*P* = 0.71PDA per *adjusted* 1SD Positive1.45 (1.22,1.72)1.45 (1.22,1.72) Negative1.54 (1.30,1.82)1.53 (1.29,1.82)*P* = 0.64*P* = 0.64NDA per *adjusted* 1SD Positive0.87 (0.75,1.02)0.88 (0.75,1.02) Negative0.76 (0.64,0.90)0.76 (0.64,0.90)*P* = 0.24*P* = 0.23HER2BIC, AUC1105, 0.681093, 0.671103, 0.661083, 0.671071, 0.661081, 0.65BMI per 1 SD at age 50 Positive129/ 3810.76 (0.49,1.17)0.78 (0.51,1.18)0.75 (0.49,1.16) Negative281/ 8240.92 (0.68,1.25)0.92 (0.68,1.25)0.90 (0.66,1.23)BMI per 1 SD at age 70 Positive1.06 (0.81,1.40)1.06 (0.81,1.40)1.06 (0.81,1.40) Negative1.26 (1.05,1.53)1.25 (1.04,1.51)1.25 (1.03,1.50)P ~for\ interaction\ with\ age~ = 0.12P ~for\ interaction\ with\ age~ = 0.14P ~for\ interaction\ with\ age~ = 0.11*P* = 0.41*P* = 0.47*P* = 0.46DA per *adjusted* 1SD Positive1.52 (1.24,1.87)1.53 (1.24,1.89)1.51 (1.23,1.85)1.52 (1.24,1.87) Negative1.31 (1.14,1.51)1.36 (1.18,1.56)1.32 (1.15,1.51)1.36 (1.18,1.56)*P* = 0.25*P* = 0.34*P* = 0.28*P* = 0.38PDA per *adjusted* 1SD Positive1.56 (1.25,1.94)1.55 (1.25,1.93) Negative1.47 (1.27,1.70)1.47 (1.27,1.70)*P* = 0.67*P* = 0.69NDA per *adjusted* 1SD Positive0.97 (0.78,1.19)0.96 (0.78,1.18) Negative0.77 (0.66,0.89)0.77 (0.67,0.89)*P* = 0.08*P* = 0.08GradeBIC, AUC1146, 0.671125, 0.671137, 0.661111, 0.661090, 0.661103, 0.65BMI per 1 SD at age 50 well differentiated96/ 2710.93 (0.60,1.45)0.94 (0.61,1.47)0.94 (0.60,1.47) moderately differentiated172/ 5110.65 (0.40,1.05)0.66 (0.41,1.06)0.64 (0.39,1.03) poorly differentiated146/ 4360.94 (0.66,1.35)0.94 (0.66,1.33)0.93 (0.65,1.33)BMI per 1 SD at age 70 well differentiated0.93 (0.60,1.45)1.02 (0.70,1.49)1.01 (0.69,1.48) moderately differentiated0.65 (0.40,1.05)1.29 (1.03,1.63)1.30 (1.04,1.64) poorly differentiated0.94 (0.66,1.35)1.22 (0.96,1.54)1.23 (0.98,1.56)P ~for\ interaction\ with\ age~ = 0.07P ~for\ interaction\ with\ age~ = 0.07P ~for\ interaction\ with\ age~ = 0.05*P* = 0.65*P* = 0.66*P* = 0.58DA per *adjusted* 1SD well differentiated1.31 (1.03,1.67)1.35 (1.06,1.72)1.31 (1.03,1.67)1.35 (1.06,1.72) moderately differentiated1.39 (1.16,1.67)1.42 (1.19,1.71)1.39 (1.17,1.66)1.43 (1.19,1.71) poorly differentiated1.35 (1.12,1.64)1.36 (1.12,1.64)1.35 (1.11,1.64)1.36 (1.12,1.64)*P* = 0.93*P* = 0.92*P* = 0.93*P* = 0.91PDA per *adjusted* 1SD well differentiated1.51 (1.17,1.95)1.51 (1.17,1.95) moderately differentiated1.49 (1.23,1.80)1.50 (1.25,1.81) poorly differentiated1.46 (1.19,1.79)1.47 (1.20,1.80)*P* = 0.98*P* = 0.98NDA per *adjusted* 1SD well differentiated0.81 (0.63,1.04)0.81 (0.63,1.04) moderately differentiated0.87 (0.72,1.05)0.86 (0.71,1.04) poorly differentiated0.76 (0.63,0.91)0.75 (0.62,0.90)*P* = 0.61*P* = 0.60SizeBIC, AUC1166, 0.691145, 0.691160, 0.681130, 0.681110, 0.681125, 0.67BMI per 1 SD at age 50 \< 1 cm106/ 2960.78 (0.51,1.20)0.78 (0.51,1.21)0.78 (0.51,1.20) 1--2 cm186/ 5520.77 (0.51,1.16)0.78 (0.52,1.18)0.76 (0.51,1.15) ≥ 2 cm137/ 4110.95 (0.61,1.49)0.93 (0.60,1.45)0.89 (0.57,1.41)BMI per 1 SD at age 70 \< 1 cm1.46 (1.03,2.07)1.45 (1.02,2.06)1.45 (1.02,2.05) 1--2 cm1.15 (0.93,1.43)1.15 (0.93,1.42)1.15 (0.93,1.42) ≥ 2 cm1.14 (0.86,1.52)1.17 (0.88,1.55)1.19 (0.90,1.57)P ~for\ interaction\ with\ age~ = 0.06P ~for\ interaction\ with\ age~ = 0.06P ~for\ interaction\ with\ age~ = 0.05*P* = 0.74*P* = 0.79*P* = 0.81DA per *adjusted* 1SD \< 1 cm1.00 (0.80,1.25)1.00 (0.80,1.26)1.00 (0.80,1.25)1.00 (0.80,1.26) 1--2 cm1.32 (1.12,1.57)1.36 (1.14,1.61)1.32 (1.11,1.56)1.35 (1.14,1.60) ≥ 2 cm1.81 (1.45,2.25)1.83 (1.47,2.27)1.82 (1.46,2.26)1.84 (1.48,2.29)*P* \< 0.01*P* \< 0.01*P* \< 0.01*P* \< 0.01PDA per *adjusted* 1SD \< 1 cm1.04 (0.83,1.31)1.04 (0.83,1.30) 1--2 cm1.48 (1.24,1.77)1.48 (1.24,1.77) ≥ 2 cm2.06 (1.61,2.63)2.08 (1.63,2.65)*P* \< 0.01P \< 0.01NDA per *adjusted* 1SD \< 1 cm0.93 (0.75,1.16)0.95 (0.76,1.17) 1--2 cm0.80 (0.67,0.95)0.80 (0.67,0.95) ≥ 2 cm0.71 (0.57,0.88)0.70 (0.56,0.87)*P* = 0.20*P* = 0.14Nodal statusBIC, AUC1074, 0.691062, 0.691075, 0.681052, 0.681041, 0.681054, 0.67BMI per 1 SD at age 50 Positive116/ 3411.09 (0.68,1.75)1.09 (0.68,1.73)1.02 (0.63,1.63) Negative288/ 8440.78 (0.58,1.04)0.78 (0.58,1.05)0.78 (0.58,1.04)BMI per 1 SD at age 70 Positive1.12 (0.81,1.53)1.11 (0.82,1.51)1.10 (0.81,1.49) Negative1.24 (1.04,1.49)1.24 (1.04,1.48)1.25 (1.04,1.49)P ~for\ interaction\ with\ age~ = 0.04P ~for\ interaction\ with\ age~ = 0.04P ~for\ interaction\ with\ age~ = 0.03*P* = 0.46*P* = 0.47*P* = 0.56DA per *adjusted* 1SD Positive1.90 (1.49,2.43)1.89 (1.49,2.41)1.92 (1.51,2.46)1.91 (1.51,2.43) Negative1.24 (1.08,1.42)1.27 (1.11,1.45)1.24 (1.09,1.42)1.27 (1.11,1.45)*P* \< 0.01*P* \< 0.01*P* \< 0.01*P* \< 0.01PDA per *adjusted* 1SD Positive2.11 (1.62,2.75)2.13 (1.64,2.78) Negative1.34 (1.16,1.54)1.34 (1.17,1.55)*P* \< 0.01*P* \< 0.01NDA per *adjusted* 1SD Positive0.67 (0.53,0.85)0.68 (0.54,0.85) Negative0.86 (0.75,0.99)0.86 (0.75,0.98)*P* = 0.07*P* = 0.09*Abbreviations*: *AUC* area under the receiver operating characteristic curve, *BIC* Bayesian information criterion, *BMI* body mass index, *CI* confidence interval, *DA* dense area, *NDA* non-dense area, *OPERA* Odds per Adjusted Standard Deviation, *PDA* percent dense area, *SD* standard deviationAll of the estimates from conditional logistic regression are adjusted for age at mammogram

Similar to risk of breast cancer overall, DA and PDA were positively associated with risk of screen-detected breast tumors of large size and positive lymph node involvement (Table [3](#Tab3){ref-type="table"}). But unlike risk of breast cancer overall, models including either DA or PDA gave the best fit when analysing tumor size and lymph node involvement. For tumor size, the model including only PDA had BIC = 647 and the model including only DA had a BIC = 648 and both the models had a AUC = 0.64. For nodal status, the model including only PDA had BIC = 611 and AUC = 0.63 while the model including only DA had a BIC = 612 and AUC = 0.64. Both MD measures were associated with similar risk estimates; about 60% increase in risk of tumors of size 2 cm and greater and about 80% increase in risk of positive lymph nodes. When restricted to small tumors (\< 2 cm), the positive association between MD and positive nodal involvement remained (results not shown). BMI and NDA were not associated with the size of the tumor and nodal involvement under any model. None of the three mammographic measures and BMI were associated with the other tumor characteristics for screen-detected cancer.Table 3Risk of screen-detected breast cancer for BMI and mammographic measures by tumor characteristicsOPERA (95% CI)Cases/ controlsBMI + DA + NDABMI + PDABMI + DADA + NDAPDADAERBIC, AUC659, 0.64646, 0.64646, 0.64638, 0.62625, 0.62625, 0.62BMI per 1 SD at age 50 Positive188/ 5370.95 (0.66,1.38)0.96 (0.66,1.38)0.96 (0.66,1.38) Negative45/ 1301.16 (0.52,2.59)1.14 (0.51,2.54)1.12 (0.50,2.51)BMI per 1 SD at age 70 Positive1.30 (1.05,1.61)1.30 (1.05,1.60)1.30 (1.05,1.61) Negative1.08 (0.65,1.80)1.08 (0.65,1.80)1.09 (0.65,1.82)P ~for\ interaction\ with\ age~ = 0.39P ~for\ interaction\ with\ age~ = 0.40P ~for\ interaction\ with\ age~ = 0.40*P* = 0.79*P* = 0.80*P* = 0.82DA per *adjusted* 1SD Positive1.16 (0.99,1.36)1.17 (0.99,1.37)1.16 (0.99,1.37)1.17 (0.99,1.37) Negative1.30 (0.92,1.82)1.31 (0.92,1.85)1.29 (0.92,1.81)1.30 (0.92,1.84)*P* = 0.57*P* = 0.56*P* = 0.59*P* = 0.58PDA per *adjusted* 1SD Positive1.17 (0.99,1.38)1.17 (0.99,1.39) Negative1.36 (0.94,1.96)1.35 (0.94,1.94)*P* = 0.46*P* = 0.49NDA per *adjusted* 1SD Positive0.99 (0.83,1.16)0.99 (0.83,1.17) Negative0.87 (0.61,1.23)0.88 (0.62,1.24)*P* = 0.53*P* = 0.55PRBIC, AUC652, 0.65640, 0.65640, 0.65634, 0.63622, 0.62622, 0.62BMI per 1 SD at age 50 Positive126/ 3620.95 (0.63,1.43)0.93 (0.62,1.40)0.94 (0.63,1.42) Negative106/ 3011.10 (0.62,1.97)1.10 (0.61,1.96)1.07 (0.60,1.90)BMI per 1 SD at age 70 Positive1.48 (1.14,1.93)1.47 (1.13,1.91)1.48 (1.14,1.93) Negative1.01 (0.74,1.37)1.00 (0.74,1.36)1.01 (0.74,1.37)P ~for\ interaction\ with\ age~ = 0.23P ~for\ interaction\ with\ age~ = 0.21P ~for\ interaction\ with\ age~ = 0.22*P* = 0.17*P* = 0.17*P* = 0.17DA per *adjusted* 1SD Positive1.21 (0.99,1.48)1.21 (0.99,1.49)1.19 (0.97,1.46)1.19 (0.97,1.46) Negative1.18 (0.95,1.45)1.20 (0.97,1.48)1.17 (0.95,1.45)1.20 (0.97,1.48)*P* = 0.84*P* = 0.94*P* = 0.92*P* = 0.98PDA per *adjusted* 1SD Positive1.20 (0.97,1.49)1.18 (0.96,1.46) Negative1.24 (1.00,1.54)1.23 (0.99,1.53)*P* = 0.84*P* = 0.79NDA per *adjusted* 1SD Positive1.03 (0.84,1.27)1.03 (0.84,1.26) Negative0.88 (0.70,1.10)0.88 (0.70,1.11)*P* = 0.30*P* = 0.33HER2BIC, AUC638, 0.66627, 0.65626, 0.65619, 0.63608, 0.63607, 0.63BMI per 1 SD at age 50 Positive73/ 2200.95 (0.56,1.63)0.93 (0.56,1.55)0.95 (0.56,1.60) Negative153/ 4310.94 (0.60,1.47)0.95 (0.60,1.49)0.94 (0.60,1.48)BMI per 1 SD at age 70 Positive0.91 (0.61,1.34)0.92 (0.63,1.34)0.92 (0.62,1.34) Negative1.41 (1.11,1.79)1.40 (1.10,1.78)1.40 (1.10,1.79)P ~for\ interaction\ with\ age~ = 0.35P ~for\ interaction\ with\ age~ = 0.38P ~for\ interaction\ with\ age~ = 0.36*P* = 0.16*P* = 0.17*P* = 0.17DA per *adjusted* 1SD Positive1.41 (1.08,1.84)1.40 (1.07,1.84)1.41 (1.08,1.84)1.41 (1.07,1.84) Negative1.13 (0.94,1.35)1.14 (0.95,1.37)1.13 (0.94,1.35)1.14 (0.95,1.37)*P* = 0.18*P* = 0.22*P* = 0.17*P* = 0.20PDA per *adjusted* 1SD Positive1.34 (1.02,1.77)1.35 (1.02,1.78) Negative1.17 (0.97,1.41)1.17 (0.97,1.41)*P* = 0.41*P* = 0.39NDA per *adjusted* 1SD Positive1.13 (0.85,1.50)1.13 (0.85,1.49) Negative0.91 (0.75,1.11)0.92 (0.76,1.11)*P* = 0.22*P* = 0.23GradeBIC, AUC680, 0.65660, 0.65661, 0.65647, 0.63627, 0.63628, 0.62BMI per 1 SD at age 50 well differentiated62/ 1741.09 (0.66,1.79)1.10 (0.67,1.80)1.10 (0.67,1.80) moderately differentiated104/ 2980.98 (0.54,1.75)0.99 (0.55,1.77)0.98 (0.55,1.76) poorly differentiated65/ 1920.70 (0.34,1.44)0.70 (0.35,1.43)0.70 (0.34,1.44)BMI per 1 SD at age 70 well differentiated1.05 (0.64,1.72)1.04 (0.64,1.70)1.02 (0.63,1.66) moderately differentiated1.35 (1.03,1.77)1.34 (1.02,1.76)1.35 (1.03,1.78) poorly differentiated1.30 (0.93,1.82)1.30 (0.93,1.80)1.30 (0.93,1.82)P ~for\ interaction\ with\ age~ = 0.39P ~for\ interaction\ with\ age~ = 0.40P ~for\ interaction\ with\ age~ = 0.38*P* = 0.79*P* = 0.77*P* = 0.74DA per *adjusted* 1SD well differentiated1.29 (0.96,1.74)1.33 (0.98,1.79)1.29 (0.96,1.74)1.32 (0.98,1.79) moderately differentiated1.13 (0.91,1.40)1.14 (0.92,1.41)1.13 (0.91,1.40)1.14 (0.92,1.41) poorly differentiated1.19 (0.90,1.56)1.19 (0.90,1.57)1.18 (0.90,1.56)1.18 (0.89,1.57)*P* = 0.77*P* = 0.72*P* = 0.77*P* = 0.73PDA per *adjusted* 1SD well differentiated1.40 (1.02,1.90)1.39 (1.02,1.89) moderately differentiated1.16 (0.92,1.45)1.17 (0.94,1.47) poorly differentiated1.16 (0.86,1.55)1.15 (0.86,1.54)*P* = 0.59*P* = 0.62NDA per *adjusted* 1SD well differentiated0.87 (0.64,1.20)0.88 (0.64,1.20) moderately differentiated0.97 (0.75,1.24)0.94 (0.73,1.20) poorly differentiated1.01 (0.77,1.32)1.01 (0.77,1.32)*P* = 0.78*P* = 0.80SizeBIC, AUC700, 0.67679, 0.66680, 0.67667, 0.64647, 0.64648, 0.64BMI per 1 SD at age 50 \< 1 cm76/ 2130.95 (0.60,1.52)0.96 (0.61,1.53)0.96 (0.60,1.52) 1--2 cm116/ 3390.86 (0.49,1.51)0.87 (0.50,1.54)0.86 (0.49,1.52) ≥ 2 cm49/ 1410.83 (0.32,2.14)0.83 (0.33,2.10)0.79 (0.30,2.07)BMI per 1 SD at age 70 \< 1 cm1.55 (1.05,2.28)1.54 (1.05,2.27)1.55 (1.05,2.27) 1--2 cm1.24 (0.97,1.59)1.23 (0.96,1.58)1.24 (0.97,1.60) ≥ 2 cm1.09 (0.64,1.84)1.10 (0.65,1.85)1.11 (0.66,1.88)P ~for\ interaction\ with\ age~ = 0.30P ~for\ interaction\ with\ age~ = 0.33P ~for\ interaction\ with\ age~ = 0.29*P* = 0.79*P* = 0.80*P* = 0.80DA per *adjusted* 1SD \< 1 cm0.92 (0.70,1.20)0.92 (0.70,1.20)0.91 (0.70,1.19)0.91 (0.70,1.19) 1--2 cm1.22 (0.99,1.50)1.23 (0.99,1.52)1.21 (0.98,1.50)1.23 (0.99,1.52) ≥ 2 cm1.56 (1.11,2.19)1.58 (1.12,2.22)1.57 (1.12,2.20)1.59 (1.13,2.24)*P* = 0.04*P* = 0.04*P* = 0.03*P* = 0.03PDA per *adjusted* 1SD \< 1 cm0.93 (0.71,1.22)0.92 (0.71,1.20) 1--2 cm1.26 (1.01,1.57)1.26 (1.02,1.57) ≥ 2 cm1.64 (1.13,2.38)1.66 (1.14,2.40)*P* = 0.03*P* = 0.02NDA per *adjusted* 1SD \< 1 cm0.99 (0.75,1.29)1.02 (0.78,1.33) 1--2 cm0.94 (0.76,1.16)0.93 (0.76,1.15) ≥ 2 cm0.85 (0.58,1.24)0.83 (0.57,1.21)*P* = 0.81*P* = 0.68Nodal statusBIC, AUC645, 0.65632, 0.65632, 0.65625, 0.64611, 0.63612, 0.64BMI per 1 SD at age 50 Positive39/ 1230.89 (0.30,2.69)0.97 (0.33,2.84)0.88 (0.29,2.68) Negative190/ 5390.93 (0.65,1.32)0.93 (0.65,1.32)0.93 (0.65,1.33)BMI per 1 SD at age 70 Positive1.61 (1.04,2.50)1.56 (1.01,2.42)1.61 (1.03,2.51) Negative1.17 (0.94,1.46)1.16 (0.93,1.45)1.17 (0.94,1.46)P ~for\ interaction\ with\ age~ = 0.39P ~for\ interaction\ with\ age~ = 0.46P ~for\ interaction\ with\ age~ = 0.38*P* = 0.41*P* = 0.45*P* = 0.43DA per *adjusted* 1SD Positive1.79 (1.22,2.62)1.78 (1.21,2.61)1.76 (1.22,2.56)1.78 (1.22,2.59) Negative1.11 (0.94,1.30)1.12 (0.95,1.31)1.11 (0.94,1.30)1.11 (0.95,1.31)*P* = 0.02*P* = 0.02*P* = 0.02*P* = 0.02PDA per *adjusted* 1SD Positive1.85 (1.22,2.79)1.84 (1.23,2.76)Negative1.13 (0.96,1.34)1.13 (0.96,1.34)*P* = 0.02*P* = 0.02NDA per *adjusted* 1SD Positive0.86 (0.59,1.27)0.87 (0.59,1.29) Negative0.96 (0.81,1.13)0.95 (0.81,1.13)*P* = 0.63*P* = 0.67*Abbreviations*: *AUC* area under the receiver operating characteristic curve, *BIC* Bayesian information criterion, *BMI* body mass index, *CI* confidence interval, *DA* dense area, *NDA* non-dense area, *OPERA* Odds per Adjusted Standard Deviation, *PDA* percent dense area, *SD* standard deviationAll of the estimates from conditional logistic regression are adjusted for age at mammogram

The association between risk of interval cancer and DA, NDA and PDA did not vary by any of the tumor characteristics (Table [4](#Tab4){ref-type="table"}). Higher BMI was associated with a decreased risk of negative lymph nodes at 50 years and increased risk of negative lymph nodes at 70 years.Table 4Risk of interval breast cancer for BMI and mammographic measures by tumor characteristicsOPERA (95% CI)Cases/ controlsBMI + DA + NDABMI + PDABMI + DADA + NDAPDADAERBIC, AUC373, 0.77363, 0.77380, 0.73349, 0.77339, 0.77356, 0.73BMI per 1 SD at age 50 Positive94/ 2780.71 (0.38,1.33)0.70 (0.38,1.31)0.74 (0.40,1.35) Negative45/ 1450.91 (0.51,1.61)0.88 (0.50,1.56)0.90 (0.51,1.61)BMI per 1 SD at age 70 Positive1.04 (0.71,1.51)1.03 (0.71,1.50)0.98 (0.68,1.42) Negative1.05 (0.49,2.25)0.96 (0.45,2.03)0.93 (0.44,1.97)P ~for\ interaction\ with\ age~ = 0.65P ~for\ interaction\ with\ age~ = 0.66P ~for\ interaction\ with\ age~ = 0.79*P* = 0.82*P* = 0.87*P* = 0.90DA per *adjusted* 1SD Positive2.14 (1.59,2.89)2.12 (1.58,2.85)2.13 (1.58,2.86)2.10 (1.57,2.82) Negative1.84 (1.20,2.83)1.90 (1.27,2.84)1.82 (1.20,2.73)1.85 (1.27,2.71)*P* = 0.58*P* = 0.67*P* = 0.54*P* = 0.60PDA per *adjusted* 1SD Positive2.63 (1.87,3.69)2.60 (1.85,3.64) Negative2.34 (1.46,3.76)2.26 (1.44,3.56)*P* = 0.70*P* = 0.64NDA per *adjusted* 1SD Positive0.64 (0.49,0.85)0.65 (0.49,0.85) Negative0.53 (0.35,0.81)0.53 (0.35,0.81)*P* = 0.46*P* = 0.44PRBIC, AUC362, 0.78352, 0.78370, 0.74344, 0.77334, 0.77352, 0.73BMI per 1 SD at age 50 Positive57/ 1720.56 (0.23,1.33)0.56 (0.24,1.32)0.59 (0.26,1.36) Negative80/ 2450.94 (0.58,1.53)0.91 (0.57,1.46)0.91 (0.56,1.48)BMI per 1 SD at age 70 Positive1.62 (0.94,2.80)1.54 (0.91,2.62)1.43 (0.87,2.36) Negative0.64 (0.39,1.04)0.63 (0.39,1.03)0.63 (0.38,1.02)P ~for\ interaction\ with\ age~ = 0.13P ~for\ interaction\ with\ age~ = 0.16P ~for\ interaction\ with\ age~ = 0.20*P* = 0.04*P* = 0.05*P* = 0.06DA per *adjusted* 1SD Positive2.32 (1.56,3.44)2.10 (1.46,3.01)2.32 (1.58,3.41)2.11 (1.48,3.01) Negative1.91 (1.36,2.69)2.04 (1.46,2.83)1.82 (1.32,2.52)1.92 (1.41,2.62)*P* = 0.46*P* = 0.91*P* = 0.35*P* = 0.70PDA per *adjusted* 1SD Positive2.92 (1.84,4.65)2.89 (1.84,4.56) Negative2.41 (1.67,3.49)2.29 (1.61,3.25)*P* = 0.52*P* = 0.42NDA per *adjusted* 1SD Positive0.58 (0.40,0.83)0.60 (0.43,0.86) Negative0.59 (0.43,0.82)0.59 (0.43,0.81)*P* = 0.93*P* = 0.91HER2BIC, AUC368, 0.77361, 0.76375, 0.73345, 0.76337, 0.76351, 0.73BMI per 1 SD at age 50 Positive41/ 1230.66 (0.28,1.56)0.65 (0.28,1.54)0.67 (0.28,1.58) Negative96/ 2930.91 (0.57,1.47)0.89 (0.56,1.43)0.92 (0.58,1.47)BMI per 1 SD at age 70 Positive0.91 (0.47,1.77)0.93 (0.49,1.77)0.87 (0.45,1.70) Negative1.08 (0.73,1.59)1.06 (0.72,1.55)1.01 (0.70,1.48)P ~for\ interaction\ with\ age~ = 0.78P ~for\ interaction\ with\ age~ = 0.77P ~for\ interaction\ with\ age~ = 0.88*P* = 0.62*P* = 0.68*P* = 0.66DA per *adjusted* 1SD Positive2.15 (1.39,3.30)2.19 (1.42,3.38)2.03 (1.34,3.07)2.05 (1.36,3.11) Negative1.96 (1.47,2.63)1.95 (1.48,2.58)1.95 (1.46,2.60)1.94 (1.48,2.56)*P* = 0.74*P* = 0.66*P* = 0.88*P* = 0.83PDA per *adjusted* 1SD Positive2.43 (1.50,3.95)2.29 (1.44,3.66) Negative2.43 (1.76,3.36)2.41 (1.75,3.31)*P* = 1.00P = 0.87NDA per *adjusted* 1SD Positive0.82 (0.54,1.24)0.82 (0.55,1.22) Negative0.55 (0.41,0.73)0.55 (0.41,0.74)*P* = 0.13*P* = 0.12GradeBIC, AUC386, 0.78375, 0.77387, 0.75354, 0.77343, 0.76356, 0.74BMI per 1 SD at age 50 well differentiated24/ 660.62 (0.21,1.82)0.60 (0.20,1.77)0.67 (0.24,1.91) moderately differentiated52/ 1650.40 (0.13,1.22)0.38 (0.13,1.13)0.39 (0.13,1.18) poorly differentiated61/ 1871.01 (0.62,1.66)0.98 (0.61,1.58)0.99 (0.62,1.59)BMI per 1 SD at age 70 well differentiated0.64 (0.24,1.67)0.61 (0.22,1.64)0.63 (0.24,1.65) moderately differentiated1.18 (0.66,2.11)1.23 (0.70,2.17)1.08 (0.61,1.92) poorly differentiated1.08 (0.67,1.74)1.14 (0.73,1.79)1.22 (0.80,1.86)P ~for\ interaction\ with\ age~ = 0.53P ~for\ interaction\ with\ age~ = 0.41P ~for\ interaction\ with\ age~ = 0.52*P* = 0.36*P* = 0.28*P* = 0.24DA per *adjusted* 1SD well differentiated1.61 (0.97,2.70)1.64 (0.97,2.77)1.49 (0.92,2.41)1.49 (0.92,2.43) moderately differentiated2.64 (1.70,4.11)2.77 (1.77,4.33)2.66 (1.71,4.13)2.75 (1.76,4.29) poorly differentiated1.85 (1.28,2.68)1.77 (1.28,2.45)1.86 (1.29,2.68)1.80 (1.31,2.47)*P* = 0.29*P* = 0.19*P* = 0.20*P* = 0.14PDA per *adjusted* 1SD well differentiated2.11 (1.17,3.80)1.90 (1.09,3.32) moderately differentiated2.94 (1.83,4.71)2.92 (1.82,4.69) poorly differentiated2.24 (1.51,3.33)2.27 (1.54,3.34)*P* = 0.60*P* = 0.49NDA per *adjusted* 1SD well differentiated0.78 (0.48,1.26)0.80 (0.50,1.28) moderately differentiated0.73 (0.48,1.10)0.72 (0.49,1.06) poorly differentiated0.48 (0.33,0.71)0.48 (0.33,0.70)*P* = 0.20*P* = 0.16SizeBIC, AUC395, 0.78381, 0.78397, 0.75359, 0.78345, 0.77361, 0.74BMI per 1 SD at age 50 \< 1 cm25/ 700.71 (0.25,2.00)0.70 (0.25,1.99)0.69 (0.23,2.09) 1--2 cm51/ 1540.69 (0.31,1.54)0.70 (0.32,1.52)0.73 (0.35,1.52) ≥ 2 cm65/ 2040.99 (0.52,1.88)0.96 (0.51,1.78)0.99 (0.52,1.89)BMI per 1 SD at age 70 \< 1 cm0.80 (0.23,2.85)0.81 (0.23,2.89)0.82 (0.23,2.92) 1--2 cm1.03 (0.60,1.76)0.96 (0.56,1.62)0.91 (0.54,1.55) ≥ 2 cm0.92 (0.54,1.57)0.94 (0.55,1.59)0.94 (0.58,1.53)P ~for\ interaction\ with\ age~ = 0.90P ~for\ interaction\ with\ age~ = 0.95P ~for\ interaction\ with\ age~ = 0.97*P* = 0.93*P* = 0.94*P* = 0.93DA per *adjusted* 1SD \< 1 cm1.62 (0.92,2.83)1.62 (0.92,2.87)1.57 (0.91,2.70)1.56 (0.91,2.69) 1--2 cm1.65 (1.14,2.38)1.65 (1.16,2.33)1.61 (1.13,2.31)1.62 (1.15,2.28) ≥ 2 cm2.78 (1.86,4.15)2.74 (1.87,4.01)2.74 (1.85,4.06)2.71 (1.87,3.93)*P* = 0.11*P* = 0.11*P* = 0.09*P* = 0.08PDA per *adjusted* 1SD \< 1 cm1.76 (0.99,3.15)1.71 (0.97,2.99) 1--2 cm2.09 (1.40,3.12)2.05 (1.38,3.03) ≥ 2 cm3.50 (2.20,5.58)3.44 (2.19,5.41)*P* = 0.12*P* = 0.10NDA per *adjusted* 1SD \< 1 cm0.83 (0.53,1.29)0.83 (0.54,1.27) 1--2 cm0.54 (0.37,0.79)0.54 (0.37,0.79) ≥ 2 cm0.58 (0.40,0.83)0.58 (0.40,0.83)*P* = 0.32*P* = 0.32Nodal statusBIC, AUC354, 0.80345, 0.79362, 0.76339, 0.78331, 0.77347, 0.74BMI per 1 SD at age 50 Positive65/ 1891.34 (0.73,2.47)1.32 (0.72,2.41)1.31 (0.71,2.42) Negative71/ 2240.46 (0.23,0.93)0.45 (0.22,0.91)0.48 (0.24,0.96)BMI per 1 SD at age 70 Positive0.64 (0.36,1.14)0.65 (0.37,1.12)0.62 (0.35,1.09) Negative1.61 (1.04,2.49)1.60 (1.03,2.49)1.58 (1.03,2.41)P ~for\ interaction\ with\ age~ = 0.01P ~for\ interaction\ with\ age~ = 0.01P ~for\ interaction\ with\ age~ = 0.01*P* = 0.01*P* = 0.01*P* = 0.01DA per *adjusted* 1SD Positive2.32 (1.57,3.41)2.30 (1.60,3.31)2.23 (1.55,3.23)2.20 (1.56,3.09) Negative1.92 (1.39,2.66)1.92 (1.40,2.64)1.84 (1.35,2.52)1.85 (1.36,2.51)*P* = 0.47*P* = 0.46*P* = 0.43*P* = 0.46PDA per *adjusted* 1SD Positive2.69 (1.79,4.07)2.61 (1.76,3.88) Negative2.47 (1.69,3.61)2.32 (1.62,3.33)*P* = 0.76*P* = 0.66NDA per *adjusted* 1SD Positive0.58 (0.41,0.81)0.57 (0.41,0.80) Negative0.60 (0.43,0.84)0.62 (0.45,0.85)*P* = 0.87*P* = 0.72*Abbreviations*: *AUC* area under the receiver operating characteristic curve, *BIC* Bayesian information criterion, *BMI* body mass index, *CI* confidence interval, *DA* dense area, *NDA* non-dense area, *OPERA* Odds per Adjusted Standard Deviation, *PDA* percent dense area, *SD* standard deviationAll of the estimates from conditional logistic regression are adjusted for age at mammogram

None of the three mammographic measures were associated with risk of interval versus screen-detected breast cancer by any of the tumor characteristics (Table [5](#Tab5){ref-type="table"}). BMI was negatively associated with risk of interval versus screen-detected cancer for tumors of 1 to 2 cm in size but not after adjusting for the mammographic measures. BMI was, however, associated with decreased risk of interval cancer with positive lymph nodes compared to screen-detected cancer, both significantly and marginally significantly after adjusting for the mammographic measures (all test for heterogeneity by nodal status, *p* = 0.02, 0.03 and 0.06).Table 5Risk of interval versus screen-detected breast cancer for BMI and mammographic measures by tumor charactersiticsOPERA (95% CI)Interval/ screen-detected casesBMI + DA + NDABMI + PDABMI + DADA + NDAPDADAERBIC, AUC492, 0.70481, 0.70492, 0.67484, 0.69474, 0.69485, 0.66BMI per 1 SD Positive94/ 1880.81 (0.63,1.05)0.80 (0.62,1.04)0.79 (0.60,1.02) Negative45/ 450.77 (0.49,1.21)0.79 (0.50,1.24)0.79 (0.50,1.24)*P* = 0.82*P* = 0.95*P* = 0.98DA per *adjusted* 1SD Positive1.55 (1.20,2.02)1.58 (1.21,2.04)1.54 (1.19,1.99)1.55 (1.20,2.01) Negative1.78 (1.12,2.82)1.90 (1.20,3.00)1.78 (1.12,2.84)1.88 (1.19,2.97)*P* = 0.61*P* = 0.47*P* = 0.58*P* = 0.46PDA per *adjusted* 1SD Positive1.87 (1.41,2.48)1.86 (1.41,2.47) Negative2.22 (1.37,3.59)2.21 (1.36,3.59)*P* = 0.52*P* = 0.53NDA per *adjusted* 1SD Positive0.68 (0.53,0.89)0.67 (0.52,0.87) Negative0.63 (0.40,0.98)0.64 (0.41,1.00)*P* = 0.75*P* = 0.85PRBIC, AUC488, 0.70477, 0.70488, 0.67480, 0.69470, 0.69481, 0.66BMI per 1 SD Positive57/ 1260.75 (0.55,1.03)0.74 (0.54,1.02)0.74 (0.53,1.02) Negative80/ 1060.84 (0.61,1.16)0.85 (0.61,1.17)0.82 (0.60,1.14)*P* = 0.64*P* = 0.56*P* = 0.63DA per *adjusted* 1SD Positive1.65 (1.20,2.29)1.67 (1.21,2.30)1.59 (1.16,2.18)1.60 (1.17,2.19) Negative1.59 (1.15,2.20)1.63 (1.18,2.25)1.60 (1.16,2.22)1.64 (1.19,2.27)*P* = 0.86*P* = 0.92*P* = 0.97*P* = 0.91PDA per *adjusted* 1SD Positive2.01 (1.42,2.85)1.93 (1.38,2.71) Negative1.91 (1.34,2.70)1.94 (1.37,2.76)*P* = 0.82*P* = 0.98NDA per *adjusted* 1SD Positive0.64 (0.47,0.87)0.64 (0.47,0.87) Negative0.71 (0.51,0.99)0.71 (0.51,0.98)*P* = 0.61*P* = 0.66HER2BIC, AUC485, 0.70478, 0.69488, 0.66475, 0.69468, 0.68479, 0.65BMI per 1 SD Positive41/ 730.93 (0.61,1.42)0.92 (0.61,1.37)0.88 (0.59,1.32) Negative96/ 1530.84 (0.64,1.10)0.85 (0.65,1.12)0.84 (0.64,1.10)*P* = 0.70*P* = 0.76*P* = 0.84DA per *adjusted* 1SD Positive1.59 (1.06,2.40)1.61 (1.08,2.40)1.58 (1.06,2.35)1.58 (1.07,2.34) Negative1.51 (1.14,1.99)1.58 (1.20,2.08)1.51 (1.15,1.99)1.58 (1.20,2.08)*P* = 0.82*P* = 0.95*P* = 0.85*P* = 1.00PDA per *adjusted* 1SD Positive1.75 (1.14,2.69)1.75 (1.14,2.68) Negative1.92 (1.43,2.57)1.92 (1.43,2.58)*P* = 0.72*P* = 0.71NDA per *adjusted* 1SD Positive0.80 (0.50,1.30)0.79 (0.49,1.25) Negative0.58 (0.44,0.78)0.58 (0.44,0.78)*P* = 0.26*P* = 0.29GradeBIC, AUC497, 0.72486, 0.70495, 0.68484, 0.71473, 0.69483, 0.67BMI per 1 SD well differentiated24/ 620.88 (0.55,1.42)0.87 (0.55,1.38)0.87 (0.54,1.38) moderately differentiated52/ 1040.67 (0.45,0.98)0.68 (0.46,0.99)0.65 (0.44,0.96) poorly differentiated61/ 650.95 (0.66,1.35)1.00 (0.71,1.40)1.04 (0.75,1.44)*P* = 0.39*P* = 0.31*P* = 0.19DA per *adjusted* 1SD well differentiated1.12 (0.69,1.84)1.13 (0.69,1.83)1.11 (0.68,1.81)1.11 (0.69,1.80) moderately differentiated1.97 (1.36,2.84)1.99 (1.38,2.87)1.92 (1.34,2.74)1.93 (1.36,2.76) poorly differentiated1.52 (1.05,2.19)1.60 (1.12,2.28)1.52 (1.05,2.20)1.62 (1.14,2.30)*P* = 0.18*P* = 0.18*P* = 0.19*P* = 0.18PDA per *adjusted* 1SD well differentiated1.29 (0.79,2.11)1.29 (0.79,2.11) moderately differentiated2.16 (1.47,3.18)2.13 (1.46,3.10) poorly differentiated2.02 (1.37,2.99)2.04 (1.38,3.01)*P* = 0.23*P* = 0.24NDA per *adjusted* 1SD well differentiated0.86 (0.55,1.33)0.84 (0.54,1.30) moderately differentiated0.82 (0.56,1.20)0.81 (0.56,1.16) poorly differentiated0.45 (0.30,0.70)0.45 (0.29,0.70)*P* = 0.06*P* = 0.06SizeBIC, AUC513, 0.72498, 0.72509, 0.69500, 0.71485, 0.71497, 0.68BMI per 1 SD \< 1 cm25/ 760.74 (0.47,1.16)0.74 (0.47,1.16)0.71 (0.45,1.12) 1--2 cm51/ 1160.71 (0.48,1.05)0.70 (0.48,1.04)0.68 (0.46,1.00) ≥ 2 cm65/ 490.95 (0.64,1.40)0.97 (0.66,1.42)1.01 (0.71,1.46)*P* = 0.54*P* = 0.47*P* = 0.27DA per *adjusted* 1SD \< 1 cm1.49 (0.92,2.42)1.55 (0.97,2.50)1.52 (0.94,2.46)1.58 (0.99,2.54) 1--2 cm1.26 (0.88,1.80)1.27 (0.89,1.82)1.29 (0.91,1.83)1.31 (0.92,1.86) ≥ 2 cm2.02 (1.39,2.94)2.12 (1.46,3.07)2.04 (1.41,2.95)2.16 (1.50,3.10)*P* = 0.16*P* = 0.12*P* = 0.18*P* = 0.12PDA per *adjusted* 1SD \< 1 cm1.75 (1.08,2.82)1.81 (1.12,2.93) 1--2 cm1.48 (1.01,2.15)1.54 (1.07,2.22) ≥ 2 cm2.67 (1.77,4.03)2.70 (1.80,4.06)*P* = 0.07*P* = 0.09NDA per *adjusted* 1SD \< 1 cm0.75 (0.50,1.13)0.73 (0.49,1.10) 1--2 cm0.74 (0.53,1.02)0.72 (0.52,0.99) ≥ 2 cm0.49 (0.30,0.81)0.49 (0.30,0.81)*P* = 0.33*P* = 0.37Nodal StatusBIC, AUC481, 0.72475, 0.71487, 0.68475, 0.71469, 0.69480, 0.66BMI per 1 SD Positive65/ 390.58 (0.38,0.90)0.61 (0.41,0.93)0.64 (0.42,0.97) Negative71/ 1901.04 (0.81,1.35)1.04 (0.81,1.35)1.02 (0.79,1.32)*P* = 0.02*P* = 0.03*P* = 0.06DA per *adjusted* 1SD Positive1.75 (1.18,2.58)1.97 (1.33,2.91)1.60 (1.09,2.36)1.77 (1.22,2.55) Negative1.48 (1.12,1.95)1.49 (1.13,1.96)1.47 (1.12,1.94)1.48 (1.13,1.95)*P* = 0.48*P* = 0.23*P* = 0.71*P* = 0.43PDA per *adjusted* 1SD Positive2.47 (1.63,3.74)2.19 (1.46,3.28) Negative1.71 (1.28,2.30)1.70 (1.27,2.28)*P* = 0.13*P* = 0.29NDA per *adjusted* 1SD Positive0.44 (0.27,0.70)0.45 (0.28,0.74) Negative0.73 (0.56,0.95)0.74 (0.57,0.96)*P* = 0.05*P* = 0.07*Abbreviations*: *AUC* area under the receiver operating characteristic curve, *BIC* Bayesian information criterion, *BMI* body mass index, *CI* confidence interval, *DA* dense area, *NDA* non-dense area, *OPERA* Odds per Adjusted Standard Deviation, *PDA* percent dense area, *SD* standard deviationAll of the estimates from conditional logistic regression are adjusted for age at mammogram

The findings above were similar when we adjusted for all the confounders. No substantial differences in estimates were observed from the sensitivity analyses.

Discussion {#Sec6}
==========

As assumed in our previous paper \[[@CR6]\], that risk of screen-detected cancers mostly reflects inherent cancer risk, and the predictors of interval versus screen-detected disease mostly reflect predictors of masking, we found that both DA and PDA are positively associated with inherent risk of larger breast tumors and positive nodal involvement. Associations between DA, NDA and PDA, and risk of masking of tumors did not vary by tumor characteristics. None of the three mammographic measures were associated with differential nodal involvement for interval versus screen-detected cancer. However, BMI was associated with a decreased risk of positive nodal involvement for interval versus screen-detected cancer.

Our results are similar to those of a large study consisting of six pooled datasets, which also found DA and PDA to be associated with increased risk of larger tumors, but found only PDA to be positively associated with positive nodal status \[[@CR18]\]. Unlike our study, the pooled study \[[@CR18]\] had also found DA to be positively associated with ER+ and PR+ tumors, and NDA to be negatively associated with the size of the tumor and HER2+. A meta-analysis \[[@CR19]\], however, found no differential association between MD and risk by ER and HER2 status of tumors. The differences in the results could be due to the fact that the previous reports did not allow the relation between relative risk and BMI to depend on age.

Some studies analysing screen-detected breast cancer had also found MD to be associated with increased risk of larger tumors \[[@CR7], [@CR10]\] and positive nodal involvement \[[@CR7]\], and none of them allowed the relation between risk and BMI to depend on age. Only one study, which did not adjust for BMI, found no association between MD and size of the tumor or nodal status for screen-detected breast cancer \[[@CR9]\]. We had interpreted risk of screen-detected breast cancer to be mainly representative of risk of developing a detectable breast tumor, assuming that the cases did not have a detectable tumor at prior mammograms. As mentioned in our previous paper \[[@CR6]\], this assumption could be reasonable based on a review \[[@CR20]\] which found that within interval cases, which consists of true interval cases, false-negative cases (tumor is not identified at a mammogram due to reader error) and occult tumors (tumor is not identified at a mammogram due to high density), there was a lesser percentage of the latter two cases; false-negative cases (25--40%) and occult tumors (8--12%). Our findings, therefore, suggest there is a biological relationship between the amount of dense tissues in the breast and faster growth rate of the tumor. When restricted to small tumors (\<2 cm), the positive association between MD and positive nodal involvement remained which could indicate that besides faster growth rate, there might be another biological mechanism that is involved between dense tissues and spreading of the tumor to the lymph nodes. Overall, this would support the indication that more frequent screening schedules should be offered to women with greater age- and BMI-adjusted MD.

We found no association between any of the mammographic measures and risk of interval breast cancer by tumor characteristics. Few studies had investigated risk by tumor characteristics separately for interval cancer. One study found greater MD to be associated with increased risk of ER+ interval cancer but it had not adjusted for BMI \[[@CR9]\]. Another study found an inverse association between MD and grade of tumor for interval cancers, but it had only allowed the association between risk and BMI to be a constant. To our knowledge, none of the studies had reported on the association between BMI and risk of interval cancer by tumor characteristics after adjusting for the mammographic measures. However, our finding of BMI being associated with increased risk of interval cancer with positive lymph nodes at age 50 is consistent with earlier studies that had analysed cases overall \[[@CR21], [@CR22]\], while another study found no correlation between the number of lymph nodes affected and BMI \[[@CR23]\]. None of these studies had allowed the association with BMI to vary by age and the mean age of their study participants was younger, between 47 to 50 years. As mentioned in our previous study \[[@CR6]\], risk of interval cancer is more likely a combination of risk of developing the tumor and risk of masking, and also influenced by the rate of tumor growth. Consequently, the results for risk of interval cancer are difficult to interpret.

We found no association between all three mammographic measures and risk of interval versus screen-detected cancer by tumor characteristics. A study which had further categorised interval cancer into true interval, false negatives, minimal-sign cancers and occult tumors also found no association between PDA and risk of each of the interval cancer category mentioned above compared with screen-detected cancer for the tumor phenotype, luminal A, luminal B, HER2 and triple-negative \[[@CR24]\]. Another study, which had stratified by PDA (low versus high), found that for women with low PDA, interval cancers were more likely to be HER2+ and have positive nodal involvement compared with screen-detected cancers \[[@CR25]\]. Both the studies, however, did not adjust for BMI \[[@CR24], [@CR25]\]. Our results for BMI, however, needs to be confirmed by other studies as to our knowledge this is the first study to investigate the association between BMI and risk by tumor characteristic and taking into account the detection mode.

To our knowledge, our study is the first to estimate the differential risk of developing breast cancer and risk of masking by tumor characteristics through investigating the concurrent associations with all three mammographic measures, DA, NDA and PDA stratified by detection mode. BMI has been measured at cohort entry and we had realistically allowed the BMI association to vary by age since BMI is known to have differential associations on breast cancer risk; BMI is negatively associated with breast cancer risk for premenopausal women and positively associated with breast cancer risk for postmenopausal women \[[@CR26]\]. A limitation of our study is the sample size, especially for small subgroups. Our ER, PR and HER2 status of tumors was measured by only one pathologist using immunohistochemistry method which might lead to non-differential misclassification of the status of the tumors and this most likely will attenuate the risk estimates towards null. Other limitations have been mentioned in our previous paper \[[@CR6]\].

Conclusions {#Sec7}
===========

We found that both DA and PDA predicted inherent risk of larger breast tumors and positive nodal status. There was no differential risk of masking by tumor characteristics associated with DA, NDA and PDA. None of the three mammographic measures were associated with differential nodal involvement for interval versus screen-detected cancer. Our finding suggest that the dense tissues of the breast play a role in faster growth rate of the tumor and in spreading of the tumor to the lymph nodes that would not be explained by delay of the diagnosis due to masking.
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